World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
29495
World Ranking
17863
National Ranking
721

Michele Reni publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michele Reni sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 527 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michele Reni D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michele Reni sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michele Reni is affiliated with Vita-Salute San Raffaele University in Italy. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology with a total of 357 and 95 publications respectively.

Their work focuses on subfields including Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Surgery, and Epidemiology. These areas reflect a multidisciplinary approach to medical science, with a dominant emphasis on cancer-related research topics.

Key topics addressed in their research include:

  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Renal cell carcinoma treatment
  • Neuroendocrine Tumor Research Advances
  • PARP inhibition in cancer therapy
  • Radiomics and Machine Learning in Medical Imaging
  • Economic and Financial Impacts of Cancer

Michele Reni has published extensively in a range of scientific journals, with frequent publications in the following venues:

  • Pancreatology
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Digestive and Liver Disease
  • Endoscopy

Frequent co-authors who collaborate with Michele Reni include Massimo Falconi, Gabriele Capurso, Paolo Giorgio Arcidiacono, Marina Macchini, and Giulia Orsi, highlighting a collaborative research network that supports ongoing studies.

Notable recent papers involving this researcher span key clinical trials and studies in oncology, demonstrating contributions to the field's evolving knowledge base. Examples include:

  • Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer, 2022, Journal of Clinical Oncology
  • Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial, 2022, Journal of Clinical Oncology
  • Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study, 2021, Annals of Oncology
  • Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer., 2021, Journal of Clinical Oncology
  • Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial, 2020, Journal of Clinical Oncology

Best Publications

  • Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

    Daniel D. Von Hoff;Thomas Ervin;Francis P. Arena;E. Gabriela Chiorean

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Andrés J M Ferreri;Jean Yves Blay;Michele Reni;Felice Pasini

  • Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer

    Lucia De Monte;Michele Reni;Elena Tassi;Daniela Clavenna

  • High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

    Andrés J. M. Ferreri;Michele Reni;Marco Foppoli;Maurizio Martelli

  • Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial

    René Olivier Mirimanoff;Thierry Gorlia;Warren Mason;Martin J. Van Den Bent

  • Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

    Andrés J M Ferreri;Kate Cwynarski;Elisa Pulczynski;Maurilio Ponzoni

  • Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

    Brigitta G Baumert;Brigitta G Baumert;Monika E Hegi;Martin J van den Bent;Andreas von Deimling

  • A multicenter study of treatment of primary CNS lymphoma

    A. J.M. Ferreri;M. Reni;F. Pasini;A. Calderoni

  • INTRA- AND INTER-OBSERVER VARIABILITY IN CONTOURING PROSTATE AND SEMINAL VESICLES : IMPLICATIONS FOR CONFORMAL TREATMENT PLANNING

    Claudio Fiorino;Michele Reni;Angelo Bolognesi;Giovanni Mauro Cattaneo

  • Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    Andres J. M. Ferreri;Kate Cwynarski;Elisa Pulczynski;Christopher P. Fox

  • Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

    Michele Reni;Stefano Cordio;Carlo Milandri;Paolo Passoni

  • Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study

    Alba A. Brandes;Alicia Tosoni;Giovanna Cavallo;Michele Reni

  • Glioblastoma in adults

    Alba A. Brandes;Alicia Tosoni;Enrico Franceschi;Michele Reni

  • Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.

    Michele Reni;Gianpaolo Balzano;Silvia Zanon;Alessandro Zerbi

  • Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature

    M. Reni;A. J. M. Ferreri;M. P. Garancini;E. Villa

  • Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis.

    Giovanni Luca Ceresoli;Michele Reni;Giuseppe Chiesa;Angelo Carretta

  • The Chemokine Receptor CX3CR1 Is Involved in the Neural Tropism and Malignant Behavior of Pancreatic Ductal Adenocarcinoma

    Federica Marchesi;Lorenzo Piemonti;Giuseppe Fedele;Annarita Destro

  • Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer

    Paolo Giorgio Arcidiacono;Silvia Carrara;Michele Reni;Maria Chiara Petrone

  • Temozolomide as salvage treatment in primary brain lymphomas

    M Reni;F Zaja;W Mason;J Perry

Frequent Co-Authors

Massimo Falconi
Massimo Falconi Vita-Salute San Raffaele University
Andrés J.M. Ferreri
Andrés J.M. Ferreri Vita-Salute San Raffaele University
Claudio Doglioni
Claudio Doglioni Vita-Salute San Raffaele University
Alba A. Brandes
Alba A. Brandes Institute of Neurological Sciences
Eileen M. O’Reilly
Eileen M. O’Reilly Memorial Sloan Kettering Cancer Center
David Goldstein
David Goldstein University of New South Wales
Giampaolo Tortora
Giampaolo Tortora University of Verona
Michele Milella
Michele Milella University of Verona
Stefano Cascinu
Stefano Cascinu Vita-Salute San Raffaele University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a range of healthcare career options, many of which can be pursued online. For those with non-nursing backgrounds interested in advanced practice, direct entry msn programs for non-nursing majors online offer a fast track to becoming a nurse practitioner or clinical leader without a traditional nursing degree.

If you’re seeking a more accessible route, consider exploring the easiest nursing schools to get into, which can help ease your entry into this high-demand field. For students interested in administrative healthcare roles, accredited medical billing and coding schools online provide flexible training, often with financial aid options.

Some nursing pathways may require entrance exams, but there are programs where you may not need to take the TEAS or HESI. Wondering, do you have to take a teas test for lpn? It depends on the school, but many now offer alternatives or omit this requirement to help more candidates enter the profession.

Best Scientists Citing Michele Reni

Trending Scientists

Recently Published Articles